Providence Medical Technology announces new equity financing of $10.5 million
Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.
Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease
Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.
MVM invests €15.2m in Valneva SE
Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera
MVM Life Science Partners LLP closes MVM IV
MVM Life Science Partners LLP announces the closing of a $233 million healthcare fund, MVM IV.
Heptares and Allergan Announce Global R&D and Commercialization Partnership
Heptares and Allergan Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer's and Other Neurological Disorders
bioTheranostics Raises $32 Million in a Private Equity Financing & Announces Spinout From bioMérieux
bioTheranostics, Inc., a leader in molecular diagnostics for cancer, has announced that it has closed a $32 million financing led by MVM Life Science Partners.
MVM leads Series-D investment in ZipLine Medical, Inc.
In December 2015, MVM led the Series-D investment in ZipLine Medical, Inc.
Alliance Pharma acquires Healthcare Products from Sinclair IS Pharma plc
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, has announced that the acquisition of the Healthcare Products Business from Sinclair IS Pharma plc, and the placing to part fund this acquisition, have completed.
Amgen Announces FDA Approval of BioVex Drug Imlygic
The US FDA approved Imlygic for sale on 27 October 2015 and, in addition, the European regulator (CHMP) recommended on 23 October 2015 that Imlygic be approved by the European Commission.
Cara Therapeutics Announces Positive Results from Phase II Trial
Cara Therapeutics, Inc., a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, has announced statistically significant results from its Phase II trial of its lead kappa opioid agonist, CR845, for the treatment of moderate to severe uremic pruritus.